University of Arkansas for Medical Science
Welcome,         Profile    Billing    Logout  
 35 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barlogie, Bart
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib

No Longer Available
N/A
US
Carfilzomib
University of Arkansas, Onyx Therapeutics, Inc.
Multiple Myeloma
04/15
04/15
Zangari, Maurizio
TT4B, NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Active, not recruiting
3
382
US
M-VTD-PACE, Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, TT3-LITE Regimen (L-TT3), Velcade (bortezomib)
University of Arkansas, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
09/25
09/26
Rhee, Frits van
NCT03004287: 2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Thalidomide, Thalomid, Dexamethasone, Baycadron, Daratumumab, Darzalex, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, ASCT, Lenalidomide, Revlimid, Bortezomib, Velcade
University of Arkansas, Janssen, LP
Multiple Myeloma
10/25
10/26
NCT04396496: Treatment of POEMS Syndrome With Daratumumab

Completed
2
2
US
Daratumumab Injection, Darzalex
University of Arkansas, Janssen Scientific Affairs, LLC
POEMS Syndrome
08/23
10/23
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Oliveto, Alison
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
Muzaffar, Jameel
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
KEYNOTE-E28, NCT04429542: Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Recruiting
1
292
Canada, US, RoW
BCA101, Ficerafusp alfa, Pembrolizumab
Bicara Therapeutics, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
12/26
06/27
Atrash, Shebli
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT03773107: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Completed
1/2
12
US
Carfilzomib, Kyprolis, Ruxolitinib, Jakafi, Dexamethasone
Wake Forest University Health Sciences, Incyte Corporation, Multiple Myeloma Research Consortium, Amgen
Multiple Myeloma
11/22
02/24
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
NCT04822337: Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Recruiting
1/2
70
US
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Wake Forest University Health Sciences, Amgen, GlaxoSmithKline
Multiple Myeloma
04/29
11/32
Matin, Aasiya
ALLOHA, NCT05473910: A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Recruiting
1
63
US
SOC + TSC-100, SOC + TSC-101, Control
TScan Therapeutics, Inc.
AML, Myelodysplastic Syndromes, ALL, Adult
12/25
06/26
Davies, Faith
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Morgan, Gareth
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
ASCENT ASD, NCT04591392: Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Recruiting
N/A
250
Europe, US
reSept ASD Occluder
atHeart Medical
Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities
12/26
12/30
NCT05006404: Autus Valve Pivotal Study

Recruiting
N/A
50
US
Pulmonary Valve Replacement Surgery
Autus Valve Technologies, Inc.
Congenital Heart Disease
08/26
02/36
NCT05077774: Harmony TPV Post-Approval Study

Recruiting
N/A
150
Canada, US
Harmony TPV System, Model Numbers: HARMONY-22, HARMONY-25, and HARMONY-DCS
Medtronic Cardiovascular
Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
10/25
03/35
PIVOTAL, NCT05547165: Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting
N/A
240
US
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Nationwide Children's Hospital, National Institutes of Health (NIH), Abbott, University of Pittsburgh, University of Bristol, Dartmouth College, University of Iowa, Emory University, Cedars-Sinai Medical Center, Children's Hospital Los Angeles, National Heart, Lung, and Blood Institute (NHLBI)
Ductus Arteriosus, Patent
02/26
02/26
NCT04034498: A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects

Active, not recruiting
N/A
50
Europe, RoW
Occlutech International AB
Perimembranous Ventricular Septal Defect
06/26
07/26
Mohan, Meera
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
1/2
27
Canada, US
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
08/23
11/23
NCT04123418: A Study of WVT078 in Patients With Multiple Myeloma (MM)

Terminated
1
56
Europe, Japan, US, RoW
WVT078, WHG626
Novartis Pharmaceuticals
Multiple Myeloma (MM)
12/24
12/24
Radhakrishnan, Muthukumar
No trials found
Mathur, Pankaj
No trials found
Thanendrarajan, Sharmilan
No trials found
Pesek, Robert
No trials found
Bakhous, Aziz
No trials found
Grazziutti, Monica
No trials found
Petty, Nathan
No trials found
Crescencio, Juan
No trials found
Thanendrajan, Sharmilan
No trials found
Susanibar-Adaniya, Sandra
No trials found
Hoque, Shadiqul
No trials found
Lehman, Brittany
No trials found

Download Options